株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

片頭痛治療薬の世界市場 (2016〜2020年)

Global Migraine Drugs Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 324100
出版日 ページ情報 英文 63 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
片頭痛治療薬の世界市場 (2016〜2020年) Global Migraine Drugs Market 2016-2020
出版日: 2016年05月02日 ページ情報: 英文 63 Pages
概要

片頭痛には、重い頭痛や吐き気・嘔吐感、光・音への極度の敏感性といった症状が繰り返し襲ってくる、という特徴があります。体内のホルモン水準の変化の影響から、男性よりも女性の方が発症しやすい傾向にあります。主な治療薬として、抗炎症鎮痛剤や抗片頭痛薬、吐き気止め、トリプタン製剤などが挙げられます。世界の片頭痛治療薬市場の2016〜2020年のCAGR (複合年間成長率) は4.56%に達する、と予測されています。

当レポートでは、全世界の片頭痛(偏頭痛)治療薬市場について分析し、市場の概要や構造、市場規模の動向(今後5年間の予測値)、パイプライン製品の情報、治療クラス別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブ・サマリー

  • 分析結果の概略

第2章 分析範囲

  • 分析概要
  • 大手ベンダーの主要製品

第3章 市場分析の手法

  • 分析手法
  • 経済指標

第4章 イントロダクション

  • 市場動向の概略

第5章 疾患の概要

  • 種類
  • 病因
  • 疾患管理
  • 病態生理
  • 経済的負担

第6章 パイプライン製品の分析

  • Semprana
  • Rizaport
  • スマトリプタン
  • DFN-11
  • Lasmiditan
  • SUD001
  • AMG 334
  • DFN-02

第7章 市場環境

  • 市場概要
  • 市場規模とその予測
  • ファイブフォース分析

第8章 治療法の種類別の市場区分

  • 予防的治療
  • 早期治療

第9章 治療クラス別の市場区分

  • トリプタン
  • 麦角アルカロイド
  • その他

第10章 地域区分

  • 世界の片頭痛治療薬:地域別の詳細動向 (今後6年間分)
  • 南北アメリカ市場
  • 欧州・中東・アフリカ諸国 (EMEA) 市場
  • アジア太平洋地域市場

第11章 市場促進要因

  • 片頭痛とその治療オプションに関する認知度の上昇
  • パイプライン候補薬の仮認証
  • 巨大なアンメットニーズ
  • 片頭痛の有病者数の増加

第12章 促進要因の影響力

第13章 市場の課題

  • 適切な診断方法の欠如
  • 薬剤の副作用
  • 代替療法の人気拡大
  • ジェネリック医薬品の普及

第14章 促進要因・課題の影響力

第15章 市場の動向

  • 抗片頭痛製品・ヘッドバンド
  • 研究開発 (R&D) 投資の増額
  • 新製品の開発
  • 戦略的な事業提携

第16章 ベンダー環境

  • 競争シナリオ
  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer
  • その他の有力ベンダー

第17章 付録

  • 略語集

第18章 Technavioについて

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR9324

About Migraines

A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.

Technavio's analysts forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Migraine Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer

Other Prominent Vendors

  • Abbott
  • Aegis Therapeutics
  • Aeriel BioPharma
  • Alder Biopharmaceuticals
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • CoLucid
  • Dr. Reddy's Laboratories
  • Eisai
  • Eli Lilly
  • Ethypharm
  • IntelGenx
  • Johnson & Johnson
  • Klaria
  • Kowa Pharmaceuticals America
  • Luitpold Pharmaceuticals
  • Meda
  • Merck
  • OptiNose
  • Pfizer
  • Pozen
  • Raptor
  • RedHill
  • SUDA
  • Teva
  • TG Therapeutics
  • NValeant
  • Winston Pharmaceuticals
  • Zogenix

Market driver

  • Growing awareness about migraine and its treatment options
  • For a full, detailed list, view our report

Market challenge

  • Lack of proper diagnosis
  • For a full, detailed list, view our report

Market trend

  • Antimigraine devices and headbands
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Types
  • Cause
  • Management
  • Epidemiology
  • Economic burden
  • PART 06: Pipeline analysis
  • Semprana
  • Rizaport
  • Sumatriptan
  • DFN-11
  • Lasmiditan
  • SUD001
  • AMG 334
  • DFN-02

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type of treatment

  • Preventative
  • Abortive

PART 09: Market segmentation by therapeutic class

  • Triptans
  • Ergot alkaloids
  • Other

PART 10: Geographical segmentation

  • Global migraine drugs market by geographical segmentation 2015-2020
  • Migraine drugs market in Americas
  • Migraine drugs market in EMEA
  • Migraine drugs market in APAC

PART 11: Market drivers

  • Growing awareness about migraine and its treatment options
  • Tentative approval of pipeline candidates
  • High unmet needs
  • Increased prevalence of migraines

PART 12: Impact of drivers

PART 13: Market challenges

  • Lack of proper diagnosis
  • Adverse effects of drugs
  • Increased preference for alternative therapies
  • Generic penetration

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Antimigraine devices and headbands
  • Increase in R&D
  • Novel product innovations
  • Strategic alliances

PART 16: Vendor landscape

  • Competitive scenario
  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Percentage of migraine sufferers worldwide by gender
  • Exhibit 03: Global migraine drugs market: Pipeline portfolio
  • Exhibit 04: Global migraine drugs market 2015-2020 ($ billions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Preventative medications based on efficacy of drugs
  • Exhibit 07: Medications used based on severity of migraines
  • Exhibit 08: Percentage share of preventative and abortive migraine medications in US 2015
  • Exhibit 09: Segmentation of global migraine drugs market by therapeutic class 2015
  • Exhibit 10: Market share of triptans by ROA 2015
  • Exhibit 11: Global migraine drugs market by geography 2015
  • Exhibit 12: Global migraine drugs market by geography 2015-2020 ($ millions)
  • Exhibit 13: Migraine drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 14: Migraine drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 15: Migraine drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 16: Impact of drivers
  • Exhibit 17: Percentage of population diagnosed with migraine in US 2014
  • Exhibit 18: Impact of drivers and challenges
  • Exhibit 19: Allergan: YoY growth rate and revenue of Botox 2012-2014 ($ millions)
  • Exhibit 20: Allergan: Key takeaways
  • Exhibit 21: Endo International: Key takeaways
  • Exhibit 22: GlaxoSmithKline: YoY growth rate and revenue of Imigran/Imitrex 2012-2014 ($ millions)
  • Exhibit 23: GlaxoSmithKline: Key takeaways
  • Exhibit 24: Impax: YoY growth rate and revenue of Zomig in the US 2012-2014 ($ millions)
  • Exhibit 25: Impax: Key takeaways
  • Exhibit 26: Pfizer: YoY growth rate and revenue of Relpax 2012-2014 ($ millions)
  • Exhibit 27: Pfizer: Key takeaways
Back to Top